Abstract Noncoding RNAs (ncRNAs) represent a class of RNA molecules that typically do not code for proteins. Emerging data suggest that ncRNAs play an important role in several physiological and pathological conditions such as cancer and cardiovascular diseases, including atherosclerosis. The best-characterized ncRNAs are the microRNAs which are small, approximately 22-nucleotide sequences of RNA that regulate gene expression at the posttranscriptional level through transcript degradation or translational repression. MicroRNAs control several aspects of atherosclerosis, including endothelial cell, vascular smooth cell, and macrophage functions as well as lipoprotein metabolism. Apart from microRNAs, recently ncRNAs, especially long ncRNAs, have emerged as important potential regulators of the progression of atherosclerosis. However, the molecular mechanism of their regulation and function as well as the significance of other ncRNAs such as small nucleolar RNAs during atherogenesis is largely unknown. In this review, we summarize the recent findings in the field, highlighting the importance of ncRNAs in atherosclerosis and discuss their potential use as therapeutic targets in cardiovascular diseases.
Introduction
In recent years, there has been a surge of interest in understanding RNA biology and its implication in human health and disease processes. High-throughput transcriptome analyses have identified a large number of noncoding RNAs (ncRNAs) in the mammalian genome. Although only 1.5 % of the human genome is responsible for protein-coding genes, a vast majority of noncoding regulatory elements are transcribed into ncRNAs [1, 2] . For many years the function of these RNA molecules remained unknown, and thus they were regarded as the "dark matter" of biology. Recent findings from several studies have shown that the noncoding portion of the genome is of crucial importance for diseases and for the regulation of biological processes, including differentiation, development, posttranscriptional regulation of gene expression, and epigenetic regulation [3] [4] [5] . MicroRNAs (miRNAs), approximately 22-nt-long noncoding sequences involved in the posttranscriptional regulation of gene expression, are by far the most extensively studied ncRNAs. Initially discovered in Caenorhabditis elegans as developmental regulators [6] , miRNAs are now known to control gene expression in most animals and are involved in a wide spectrum of biological processes, including development, cell proliferation, lipid metabolism, angiogenesis, and tumorigenesis [7] [8] [9] . Apart from miRNAs, the roles of several other ncRNA species, including long ncRNAs (lncRNAs), PIWI-interacting RNAs, small nucleolar RNAs, and transcribed ultraconserved regions, have been revealed for these processes.
Cardiovascular diseases are a major health problem and the leading cause of death in the Western societies [10] . Atherosclerosis, the major form of cardiovascular disease, is a chronic inflammatory process characterized by the deposition of inflammatory plaques within the arterial wall and involves the complex interaction of several different cell types and modified lipoproteins [11] . Several studies have shown that altered ncRNA expression and function have been implicated in the atherosclerotic process.
In this review, we summarize the recent findings in the field highlighting the importance of ncRNAs, primarily miRNAs and lncRNAs during the progression of atherosclerosis.
Noncoding RNAs
Regulatory ncRNAs can be classified into three different classes on the basis of their transcript size; (1) short ncRNAs, (2) medium-sized ncRNAs, and (3) lncRNAs (Table 1 and 2). Short ncRNAs represent a class of ncRNAs smaller than 30 nt in length and include very well documented miRNAs, PIWIinteracting RNAs, and transcription-initiation RNAs. Medium-sized ncRNAs, typically 20-300 nt in length, include promoter upstream targets, small nuclear RNAs, and transcription-start-site-associated RNAs. Long ncRNAs (lncRNAs) are usually longer than 200 nt and comprise a wide variety of RNAs, including long intergenic ncRNAs, enhancer-like ncRNAs, transcribed ultraconserved regions, and natural antisense transcripts (NATs). The regulation and processing of these ncRNAs are described elsewhere [4, 12, 13] . Here, we will focus mainly on miRNAs and lncRNAs that have been established as important regulators of several aspects of atherosclerosis.
Small ncRNA (miRNA)
The most widely studied class of ncRNAs are miRNAs, which are small ncRNAs (approximately 22 nt) that in animals mediate posttranscriptional gene repression by controlling the translation of messenger RNA (mRNA) into protein [14, 15] . MicroRNAs (miRNAs) are estimated to regulate the translation of more than 60 % of protein-coding genes [16] . As a consequence, these small endogenous silencers have emerged as critical regulators of a diverse range of biological processes, including proliferation, differentiation, apoptosis, and development. Although some miRNAs regulate individual target genes, others can function as a master regulator of biological processes by controlling the expression of numerous genes involved in the same physiological pathway. In most cases, miRNAs function to modulate or fine-tune cellular phenotypes rather than working as regulatory on/off switches.
Biogenesis of miRNAs occurs through a multistep process that involves the RNase III enzymes Drosha and Dicer, and finally results in the production of mature miRNAs. The guide strand (5p) is loaded into the RNA-induced silencing complex targeting the 3′ untranslated region (UTR) of mRNA transcripts [17, 18] . After binding to the 3′ UTR of their target genes, miRNAs regulate protein expression through mRNA destabilization and/or by inhibition of translation. In order to repress the transcript, it is crucial that the nucleotides at positions 2-8 of the miRNA, the seed sequence, are almost perfectly complementary to regions at the 3′ UTR of their target genes [19] . [20, 21] . Long ncRNAs (lncRNAs) make up a large proportion of the mammalian transcriptome. There are 73,370 lncRNA entries from 1,239 organisms according to NONCODE version 3.050; however, fewer than 200 of these lncRNAs have been functionally annotated [21] . Long ncRNAs (lncRNAs) can regulate gene expression through a variety of mechanisms, including epigenetic modification of DNA, alternative splicing, posttranscriptional gene regulation, and mRNA stability and translation [22, 23] . They have been reported to control every level of the gene expression program in various physiological processes, including development, proliferation, differentiation, apoptosis, and metabolism [24] [25] [26] . Long ncRNAs (lncRNAs) can regulate gene expression by executing as signals, decoys, guides, and scaffolds and acting as repressors or activators to modulate the process of gene transcription and translation [27] . For instance, PANDA, an lncRNA induced by DNA damage from the CDKN1A promoter, acts as a decoy molecule. Specifically, PANDA limits the expression of proapoptotic genes to favor cell cycle arrest following DNA damage through the binding and sequestration of NF-YA, a nuclear transcription factor that activates the apoptotic program on DNA damage, thereby promoting cell survival [28] . Similarly, lncRNAs can also act as scaffolds bringing together multiple proteins to form ribonucleoprotein complexes. For example, the lncRNA HOTAIR acts as a scaffold for polycomb repressive complex 2 (PRC2) and the LSD1/CoREST/ REST complex, and coordinates targeting of PRC2 and LSD1 to chromatin, resulting in histone modification and transcriptional repression [29] .
Small ncRNA (miRNAs) and Atherosclerosis
MicroRNAs (miRNAs) have been primarily described in cancer, but recent exciting findings have also demonstrated a key role in cardiovascular diseases, including atherosclerosis. The progression of atherosclerosis is characterized by very well established steps, including macrophage foam cell formation, fatty streak accumulation, migration and proliferation of vascular smooth muscle cells (VSMCs), and fibrous cap formation. This multifactorial disease is caused by the interaction of many key components, including lipoproteins, macrophages, T cells, and arterial wall components such as endothelial cells (ECs) and VSMCs. A growing body of studies have shown that miRNAs regulate EC, VSMC, and macrophage functions as well lipid metabolism, thereby controlling the progression of atherosclerosis.
Lipoprotein Metabolism and miRNAs
Since the early discovery in the mammalian genome, miRNAs have become essential regulators of lipid and glucose metabolism [30] . MicroRNAs (miRNAs) such as miR-122, miR-33, miR-144, miR-758, and miR-106 have been described to play important roles in regulating lipid homeostasis by targeting crucial genes of cholesterol metabolism and fatty acid oxidation [31] [32] [33] [34] [35] [36] . Both miR-33a and miR-33b are intronic miRNAs encoded within the sterol response element binding protein genes SREBP2 and SREBP1, respectively. Both miRNAs repress the expression of genes involved in cholesterol efflux, fatty acid oxidation, and glucose production including ATP binding cassette A1 (ABCA1), carnitine Ooctanyl transferase (CROT), carnitine palmitoyltransferase 1A (CPT1A), hydroxyacyl-CoA dehydrogenase-3-ketoacylCoA (HADHB), AMP-activated protein kinase, phosphoenolpyruvate carboxykinase (PCK1), and glucose 6-phosphatase (G6PC) [33, 37] . Recent reports in different animal models have shown that the therapeutic inhibition of miR-33 increases the levels of circulating high-density lipoprotein (HDL) cholesterol [38•, 39••, 40•] . Similar effects were observed in mice lacking miR-33. As expected from its significant effect on raising plasma HDL cholesterol levels, antagonism of miR-33 attenuates the progression and enhances the regression of atherosclerosis in mice. Similarly, genetic ablation of miR-33 markedly reduces atherogenesis in apolipoprotein E deficient mice. In addition to miR-33, other miRNAs, including miR-144 and miR-748, also regulate ABCA1 expression. Interestingly, silencing miR-144 increases plasma HDL cholesterol levels in mice, suggesting that miR-144 inhibition might be useful for treating atherosclerosis.
High levels of circulating low-density lipoprotein (LDL) are the major risk factor that predisposes an individual to have coronary heart disease. In this regard, hepatic miR-122 expression and hepatic miR-30c expression have been shown to control plasma LDL cholesterol levels. Two classic studies demonstrated that antagonism of miR-122 results in a significant reduction of circulating LDL cholesterol levels in mice and nonhuman primates. The most abundant miRNA in the liver is miR-122, and its absence decreases the hepatic expression of genes involved in cholesterol synthesis and lipoprotein secretion. One recent study has also shown that miR-30c expression also controls LDL cholesterol levels by regulating lipid biosynthesis and the secretion of lipoproteins in the liver. Further, miR-30c regulates the expression of microsomal triglyceride transfer protein, which is essential for the assembly of lipoproteins in the liver as well as LPGAT1, which is involved in lipid biosynthesis. Intriguingly, hepatic miR-30c overexpression results in a marked reduction of plasma cholesterol levels, thereby ameliorating the progression of atherosclerosis in mice [41••] .
Endothelial Dysfunction and miRNAs
The initial step in the development of atherosclerotic lesions is mediated by the endothelium. Many stimuli, such as oxidized LDLs (ox-LDLs), cholesterol, diabetes mellitus, and hypertension, impair endothelial function, increasing permeability and expression of leukocyte adhesion proteins, such as Eselectin and vascular cell adhesion molecule 1 (VCAM-1), thereby allowing leukocytes to migrate into the vessel wall. The first evidence of the important role of miRNAs and endothelial dysfunction was provided by the observation that silencing Dicer in ECs impairs angiogenesis in vitro. Several studies have recently shown the importance of some specific miRNAs, including miR-126, miR-31, miR-181b, and miR92a, in regulating EC functions. It has been found that miR-126 is highly expressed in ECs and regulates monocyte adhesion by directly targeting VCAM-1 [42] . Administration of miR-126 in a mouse model of atherosclerosis may reduce macrophage and apoptotic cell content, thereby limiting the size of the plaque and conferring a milder inflammatory reaction [43] . In contrast, the contribution of miR-126 in neointimal hyperplasia and the atheroprone role of this miRNA in smooth muscle cells have recently been shown [44] . In addition to miR-126, miR-31 and miR-17-3p also regulate vascular inflammation by controlling the expression of VCAM-1, intercellular adhesion molecule 1, and E-selectin [45] . VCAM-1 levels in ECs are also regulated by miR-21, but its contribution during the progression of atherosclerosis is somehow controversial. Although miR-21 is upregulated in human atherosclerotic plaques [46] and aberrant expression of this miRNA was found in vascular neointimal lesion formation [47] , miR-21 inhibits peroxisome-proliferator-activated receptor α, leading to enhanced expression of VCAM-1 [48] . Whether an increase in the expression of miR-21 in ECs is beneficial or deleterious remains to be clarified. In a very recent study, Di Bernardini et al. [49] suggested that in induced pluripotent stem cells predifferentiated with vascular endothelial growth factor, miR-21 targets phosphatase and tensin homolog/AKT and induces transforming growth factor β 2 , therefore mediating endothelial differentiation, which might provide the basis for stem cell therapy for vascular diseases. Other miRNAs are involved in the modulation of proinflammatory genes in ECs, such as miR-10a, which inhibits VCAM-1 and E-selectin or the NF-κB pathway [50] . This signaling pathway is also modulated by miR-181b, which directly targets importin subunit α 4 (KPNA4), a protein required for NF-κB nuclear translocation [51•] . Recently, the same group described that systemic delivery of miR-181b in apolipoprotein E deficient mice inhibits NF-κB and atherosclerosis through the inhibition of importin α 3 [52] . Both miR-146a and miR-146b have to be added to this miRNAmediated NF-κB regulatory network in ECs. Both miRNAs control the activation of the early growth response and activator protein 1 pathways and directly target HuR, which promotes endothelial activation by antagonizing endothelial nitric oxide synthase (eNOS) expression [53] . Both miR-155 and miR-221/222 also play a role in modulating endothelial inflammation by downregulating eNOS expression [54, 55] , ETS1, and its downstream inflammatory molecules in ECs [56] . Neovessel formation can also be regulated by miR-222, which silences signal transducer and activator of transcription 5A (STAT5A) [57] . In fact, there is a negative correlation between miR-222 and STAT5A in ECs from advanced neovascularized plaques [57] . A recently discovered miRNA that regulates endothelial inflammation by targeting tissue inhibitor of metalloproteinase 3 is miR-712, an atypical mechanosensitive miRNA originating from the RNA 45S gene [58] . Moreover, miR-205 was identified as a human homologue of the murine miR-712 and was shown to share the same seed sequence [58] .
Angiogenesis is also regulated by the miR-17-92 cluster. Vascular endothelial growth factor regulates the expression of miR-17-92 and targets thrombospondin 1, an antiangiogenic molecule [59] . However, the role of every member of the miR-17-92 cluster in regulating angiogenesis is not totally clear and appears to be complex as it has shown contradicting roles in different reports [59] . Shear stress also regulates EC activation through miRNAs. In this regard, atheroprotective laminar shear flow downregulates miR-92a, a member of the miR-17-92 cluster, and increases the expression of some targets such as Krüppel-like factor 2 and Krüppel-like factor 4 (KLF4) [60] . Loyer et al. [61] reported for the first time the proatherogenic role of miR-92a, which specifically promotes endothelial dysfunction and inflammation in a low-dependent manner. They identified suppressor of cytokine signaling 5 as a new target for miR-92-a and signal transducer and activator of transcription 3 as a transcription factor that regulates its expression. Although the role of miR-27 during atherosclerosis has not been elucidated, there is good reason to speculate that miR-27 may serve as a potential indicator for atherosclerosis. Most evidence suggests that the miR-27 family may be a genuine proatherogenic gene and that it may play an important role in the regulation of angiogenesis, adipogenesis, inflammation, lipid metabolism, oxidative stress, and insulin signaling [62] . Genetic silencing of Dicer and Drosha led to significantly reduced miR-27 expression in ECs [63] . Akhtar et al. [64] showed that increased expression of metalloproteinase 13 correlated with down-regulation of miR-27b [64] , indicating that miR-27 may contribute to plaque formation in atherosclerosis by regulating the expression of metalloproteinase 13. Further, miR-27a/b also targets semaphorin 6A, thereby regulating EC adhesion and angiogenesis [65, 66] .
Aging is another risk factor for the development of atherosclerosis. Since EC senescence contributes to age-related impairment of angiogenesis and vascular relaxation, miRNAs involved in the senescence process may be also related to plaque formation. In this regard, it has recently been described that miR-217 exerts negative effects on the vascular endothelium by enhancing EC senescence [67] , as does miR-34a [68] . In contrast, miR146a has been shown to delay EC senescence [69] .
VSMC Regulation and miRNAs
VSMC migration and proliferation are crucial in atherosclerosis progression. The switch of VSMC phenotype contributes to neointima and plaque formation. MicroRNAs (miRNAs) are essential for VSMC development and function by regulating both differentiation and proliferation. In addition, some endothelial miRNAs can be exported via exosomes and affect VSMC functions. Importantly, alterations in EC-VSMC communication have been implicated in atherosclerosis. Increased miR-21 expression regulates VSMC function by targeting tropomyosin 1 [70] , programmed cell death 4 [47, 71] , sprouty 2, and peroxisome-proliferator-activated receptor α in atherosclerosis [72] . Another well-known miRNA that has been shown to regulate VSMC phenotype and function is miR-143/145. Several studies have demonstrated that miR-143/145 plays a key role in smooth muscle cell phenotypic switching in response to vascular injury. The effect of miR-143/145 in controlling smooth muscle cell phenotypic switching is likely mediated through the targeting of multiple transcription factors, such as KLF4, Krüppel-like factor 5, and a member of the ETS oncogene family (ELK-1). The activities of these transcription factors are linked to the repression of smooth muscle cell differentiation genes [73] [74] [75] [76] . Moreover, loss of miR-145 results in the formation of podosomes, which are actin-rich membrane protrusions that are involved in VSMC migration [77] . In addition to the miR-143/145 cluster, miR146a and miR1/133 can also modulate KLF4 expression in VSMCs [78] [79] [80] [81] .
In a series of elegant, yet independent studies, it has recently been shown that miR-29 regulates vascular integrity by controlling multiple genes encoding extracellular matrix proteins, including multiple collagens, fibrilins, and elastin [82] .
Expression of miR-29 is upregulated in the arteries isolated from a mouse model of aneurysms and in biopsy material from human thoracic aneurysms. Importantly, inhibition of miR-29 enhances elastin levels in cells haploinsufficient for elastin and improves bioengineered vessels by increasing elastin expression [83•] . Expression levels of miR-29 are regulated during aging in the arterial wall. Arteries isolated from old mice expressed significantly higher levels of miR-29 compared with young mice. Moreover, miR-29 expression is also upregulated in aortas isolated from mice fed a high-fat diet. Together, these observations suggest a potential role of this miRNA during the progression of atherosclerosis, where aging and dyslipidemia are major risk factors.
Several miRNAs has been shown to play important roles in regulating VSMC proliferation, including miR-221/222, miR-208, and miR-132. Expression of miR-221/222 is upregulated and localized in the VSMCs of injured vascular walls, resulting in VSMC proliferation and neointimal hyperplasia [84, 85] . Zhang et al. 86] demonstrated that insulin upregulated miR-208 expression and increased VSCM proliferation by targeting p21. Finally, miR-132 has been reported as a novel regulator of VSCM proliferation that represses neointimal formation by inhibiting leucine-rich repeat (in Flightless 1) interacting protein 1 expression [87] .
Although let-7 is important during cancer development, it has recently been identified as a key player in cardiovascular disease. It has nine members in humans. Yu et al. [88] have described that let-7d inhibits VSMC proliferation by targeting KRAS. Moreover, ox-LDL inhibited let-7 g expression via the lectin-like ox-LDL receptor 1/reactive oxygen species/ extracellular-signal-regulated kinase/activator protein 1 pathway and, inversely, let-7 g was shown to directly target lectinlike ox-LDL receptor 1 to compromise a negative-feedback regulation that was involved in VSMC proliferation and migration [89] . Recently, let-7 g overexpression has been described to negatively regulate apoptosis induced by ox-LDL in vascular ECs by targeting capase 3 expression [90] . Liao et al. [91] have recently shown that decreased let-7 g levels impair endothelial function and increase the risk of cardiovascular disease by targeting transforming growth factor β and sirtuin 1 signaling.
Arterial calcification is a key pathological component of atherosclerosis, and a hallmark of it is the phenotypic transition of VSMCs to osteoblast-like cells. Several studies have demonstrated that miRNAs also regulate osteoblast differentiation. In a recent study, the role of miR-133 in regulating VSMC-mediated arterial calcification via direct suppression of Runt-related transcription factor 2, a transcription factor involved in osteogenesis, was characterized [92] . Additionally, miR-181a protects against angiotensin II-induced osteopontin expression in VSMCs [93] .
Altogether, these studies strongly suggest that miRNAs regulate multiple aspects of VSMC biology, including phenotypic differentiation, migration, and proliferation.
Macrophage Activation and miRNAs
One of the pathological hallmarks of atherosclerosis is the accumulation of cholesterol by macrophages [11] . The lipidladen macrophages are named foam cells, and they contribute significantly to the formation of atherosclerotic lesions. Moreover, macrophages are cells involved in the innate immune system and can also release inflammatory substances that influence atherosclerosis. Recently, some studies have reported that miRNAs play an important role in foam cell formation and the inflammation process in atherosclerosis. It was recently determined that miR-9 could functionally decrease the formation of foam cells from THP-1-derived macrophages by reducing the level of acetyl-CoA acetyltransferase 1 following the enzymatic activity [94] . However, further studies are needed to rule out if miR-9 affects lipid uptake, lipid binding, or cholesterol efflux from ox-LDL. Moreover, miR-9 regulates the expression of peroxisome-proliferatoractivated receptor δ in human monocytes during the inflammatory response [95] . It has been found that miR-125a-5p is important not only in endothelial dysfunction but also during foam cell formation. It has been shown that miR-125a-5p inhibits lipid uptake and the inflammatory responses in ox-LDL-stimulated monocytes/macrophages through modulation of oxysterol-binding-protein-like protein 9 expression [96] . Silencing of the endogenous miR-155 in macrophages significantly enhances lipid uptake, upregulates the expression of scavenger receptors, and promotes the release of several proinflammatory cytokines, including IL-6, IL-8, and TNF-α [97] . Moreover, miR-155 promoted the expression of chemokine (C-C motif) ligand 2 and suppressed B-cell leukemia/ lymphoma 6, a transcription factor that inhibits NF-κB [98] . However, another study provided opposite results showing that hematopoietic deficiency of this miRNA increased the size and the instability of the plaque, possibly by the inhibition of lipid uptake and the inflammatory responses in monocytes [99] . Thus, more studies need to be conducted in order to elucidate the role of miR-155 during the progression of atherosclerosis.
Two main risk factors, hyperlipidemia and infectious disease, point toward the innate immunity mechanism as a potential contributor to proatherogenic inflammation. Toll-like receptors (TLRs) are proinflammatory sensors of pathogens and oxidized lipids that control inflammation in infectious diseases and atherosclerosis. In addition to regulating inflammation by controlling NF-κB activation, TLR ligands also stimulate the expression of several miRNAs, including miR-155, miR-146, and miR-147, associated with inflammation and the progression of atherosclerosis. It has been found that miR-146a inhibits accumulation of ox-LDL-induced lipid and the inflammatory response by targeting TLR4 [100] . Further, miR-147 has also been described as a negative regulator of the TLR-associated signaling events in macrophages [101] .
Long ncRNAs and Atherosclerosis
Although lncRNAs are reported in a wide range of physiological functions, their role in the progression of cardiovascular disease and atherosclerosis is poorly known and is limited to few examples. Myocardial-infarction-associated transcript was one of the earliest lncRNAs identified as a risk factor for cardiovascular disease. Particularly, through a large-scale case-control association study, it was shown that altered expression of myocardial-infarction-associated transcript by one particular SNP confers susceptibility to myocardial infarction [102] . The molecular mechanism underlying this correlation, however, is still unknown. Later several studies found that the chromosome arm 9p21 locus is the strongest genetic risk factor for coronary artery disease [103] [104] [105] . This region contains a long intergenic ncRNA designated antisense ncRNA in the INK4 locus (ANRIL, also known as CDKN2B antisense RNA 1). ANRIL is transcribed in an antisense direction with respect to the primary INK4 and ARF transcripts. It is known to be involved in tumor suppression. Specifically, it binds to components of polycomb repression complex 1 and PRC2 and mediates transcriptional repression of the INK4 locus by H3K27 trimethylation in cis [106, 107] . In addition, there is ample of evidence demonstrating a direct role of ANRIL in cardiovascular diseases. ANRIL is expressed in many cells and tissues involved in the atherogenic processes, including smooth muscle cells, vascular ECs, human monocyte-derived macrophage cells, and RNA extracted from carotid arteries [108] . A recent study has shown that increased expression of ANRIL transcripts is directly correlated with the severity of atherosclerosis. ANRIL regulates target genes in trans, leading to increased cell proliferation, increased cell adhesion, and decreased apoptosis, all processes essential for atherosclerosis. This trans regulation is dependent on Alu motifs, which are present on the promoters of ANRIL target genes and are mirrored in ANRIL RNA transcripts [108] . Moreover, another study showed that ANRIL regulates the expression of ADIPOR1, VAMP3, and C11ORF10 in a time-dependent manner. These genes demonstrate a well-described role in fatty acid and glucose metabolism as well as inflammation. Furthermore, the study found that the VAMP3 gene locus is a risk factor for coronary artery disease and C11ORF10 carries a risk variant for metabolic disorders [109] . All these data present strong evidence for the role of ANRIL in cardiovascular diseases.
There have been several studies aimed at identifying and underlining the specific roles of lncRNAs in a tissue-specific manner in vascular biology. For example, Lnc-Ang362 was identified as a differentially expressed ncRNA in rat VSMCs in response to angiotensin II using transcriptome and epigenomic profiling. The study found that miR-221 and miR-222, which are associated with smooth muscle cell proliferation and neointimal hyperplasia in response to vascular injury, are cotranscribed with Lnc-Ang362. Knockdown of Lnc-Ang362 reduces the expression of these miRNAs and VSMC proliferation [25] . Apart from VSMCs, EC integrity is an important component of normal vasculature, which can be deregulated during atherosclerosis. In particular, eNOS is an important enzyme that maintains this integrity by producing nitric oxide. NAT to eNOS, eNOS antisense, is induced by hypoxia in ECs and regulates eNOS expression in a posttranscriptional manner under normoxic and hypoxic conditions. Overexpression of eNOS antisense reduces eNOS expression, and inhibition causes the opposite effect [110, 111] . Similarly, TIE-1, a cell-surface tyrosine kinase receptor for angiopoietin ligands important for vascular development in vertebrates, is regulated in vitro and in vivo by its long noncoding antisense transcript TIE-1AS lncRNA. TIE-1AS lncRNA binds to TIE-1 mRNA, resulting in downregulation of TIE-1 and results in defects in EC contacts. Overexpression of TIE-1AS lncRNA resulted in defects in EC junctions and tube formation [112] . A very recent study showed that another NAT, apolipoprotein A-I (APOA1) antisense, acts as a negative transcriptional regulator of APOA1 both in vitro and in vivo [113] . APOA1 is the major protein component of HDL, an important lipoprotein that is involved in reverse cholesterol transport and is associated with reduced atherosclerosis [114] . This study found that APOA1 antisense can modulate distinct histone methylation patterns and thereby expression of APOA1 as well as two neighboring genes through the recruitment of histone-modifying enzymes [113] . Moreover, lncRNAs are implicated in inflammation and the innate immune response as well. Recently, lncCox2, an lncRNA proximal to the COX2 gene, was identified using whole transcriptome analysis of mouse bone-marrow-derived macrophages stimulated with TLR ligands. This study showed that lncCox2 can mediate both activation and repression of distinct classes of immune genes [115] .
Taken together, these observations suggest that lncRNAs are emerging players in cardiovascular diseases and atherosclerosis. They can affect several processes associated with atherosclerosis, including VSMC proliferation, endothelial function, lipid metabolism, and inflammation. However, our knowledge of lncRNAs, their regulation, and their functions is still in its infancy and, as such, requires further investigations to identify and characterize myriads of other lncRNAs and explore their potential therapeutic applications.
Concluding Remarks
Noncoding RNAs (ncRNAs) have emerged as critical regulators of several disease processes, including atherosclerosis. MicroRNAs (miRNAs), in particular, are well documented in terms of dysregulation of several aspects of atherosclerosis, including lipid metabolism, cholesterol homeostasis, endothelial dysfunction, and inflammation. Their conservation between species suggests that the biological pathways where miRNAs play a role may have been conserved. For that reason, miRNAs have a therapeutic potential, and different approaches have been undertaken to examine this. For example, antagonists of miR-33 in vivo increase plasma HDL levels and attenuates the progression of atherosclerosis in mice and nonhuman primates [39••, 40•] . Moreover, signaling pathways that are regulated by miRNAs could be potential therapeutic targets as well. On the other hand, although several thousand lncRNAs have been identified in mammals, only a few of them are functionally annotated, especially in association with cardiovascular diseases. However, given the rapid advancement in the field and immense attention given to lncRNAs in recent times, we anticipate that the field will witness major discoveries regarding the role of lncRNAs in many cellular and molecular processes. Knowledge of these processes will be of substantial value to identify novel genes and molecular pathways for therapeutic interventions against diseases, including atherosclerosis.
